Literature DB >> 6447728

Self recognition by autologous mixed lymphocyte reaction-primed cells.

K Tomonari, A Wakisaka, M Aizawa.   

Abstract

Human T cells were separated with neuraminidase-treated autologous erythrocytes into auto-rosette-forming cells (ARFC) and non-ARFC (N-ARFC). These 2 subsets were examined for reactivity to autologous non-T cells. When N-ARFC were stimulated by autologous non-T cells, blastogenesis was weak; ARFC, however, proliferated vigorously. ARFC were revealed to be the major subset that responded and proliferated in autologous mixed lymphocyte reaction (AMLR). AMLR-primed cells were restimulated by autologous or allogeneic non-T cells to study self recognition in relation to HLA complex. Self recognition by AMLR-primed cells was closely related to HLA complex, and absolute identity of HLA complex was necessary to recognize allogeneic cells as self. In addition, in respect to the responder cell difference between AMLR and allogeneic MLR, the reactivity of 2 kinds of cells (i.e., AMLR-primed cells and alloreactive cells) strongly suggested that autoreactive T cells were distinguished from alloreactive T cells.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6447728

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Inhibition of autologous mixed lymphocyte reaction by monoclonal antibodies specific for the beta chain of HLA-DR antigens.

Authors:  M Kasahara; H Ikeda; K Ogasawara; N Ishikawa; T Okuyama; Y Fukasawa; H Kojima; H Kunikane; S Hawkin; T Ohhashi
Journal:  Immunology       Date:  1984-09       Impact factor: 7.397

2.  Characterization of human peripheral blood T lymphocytes bearing receptors for autologous erythrocytes and T lymphocytes lacking these receptors.

Authors:  T Sakane; M Honda; Y Taniguchi; H Kotani; Y Niwa
Journal:  J Clin Immunol       Date:  1982-01       Impact factor: 8.317

3.  The alpha chain, not the beta chain of HLA-DR antigens participates in activation of T cells in autologous mixed lymphocyte reaction.

Authors:  R Palacios; L Claesson; G Möller; P A Peterson; E Möller
Journal:  Immunogenetics       Date:  1982       Impact factor: 2.846

4.  Generation of suppressor cells in the autologous mixed lymphocyte reaction.

Authors:  P Fitzharris; R A Knight
Journal:  Clin Exp Immunol       Date:  1981-10       Impact factor: 4.330

5.  Autologous rosette-forming T cells regulate responses of T cells. Phenotypic and functional analysis of suppressor cells generated from autologous rosette-forming T cells after autologous mixed lymphocyte reactions.

Authors:  S Kumagai; I Scher; I Green
Journal:  J Clin Invest       Date:  1981-08       Impact factor: 14.808

6.  Differences in the kinetics of the autologous mixed lymphocyte reaction between the various connective tissue diseases.

Authors:  A Laffón; J Alcocer-Varela; D Alarcón-Segovia
Journal:  Rheumatol Int       Date:  1983       Impact factor: 2.631

7.  Cellular bases of the production of and response to interleukin-2 in man: role of autologous rosette-forming T-cell subsets defined with monoclonal antibodies.

Authors:  E Fishbein; J Alcocer-Varela; D Alarcón-Segovia
Journal:  Immunology       Date:  1983-10       Impact factor: 7.397

8.  Differences in the production of and/or the response to interleukin-2 by T lymphocytes from patients with the various connective tissue diseases.

Authors:  J Alcocer-Varela; A Laffón; D Alarcón-Segovia
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

9.  Defective monocyte production of, and T lymphocyte response to, interleukin-1 in the peripheral blood of patients with systemic lupus erythematosus.

Authors:  J Alcocer-Varela; A Laffon; D Alarcón-Segovia
Journal:  Clin Exp Immunol       Date:  1984-01       Impact factor: 4.330

10.  Rosetting of activated human T lymphocytes with autologous erythrocytes. Definition of the receptor and ligand molecules as CD2 and lymphocyte function-associated antigen 3 (LFA-3).

Authors:  M L Plunkett; M E Sanders; P Selvaraj; M L Dustin; T A Springer
Journal:  J Exp Med       Date:  1987-03-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.